GE HealthCare agrees to buy SOFIE Biosciences for $945 million in cash

By Public Technologies
  • GE HealthCare agreed to buy PET radiopharmaceutical contract manufacturer SOFIE Biosciences from Trilantic North America for USD 945 million cash.
  • Closing is expected in the first half of 2027; SOFIE would be folded into GE HealthCare’s Pharmaceutical Diagnostics segment.
  • Deal adds a U.S. “final mile” PET supply network with 15 sites operating 21 cyclotrons, broadening GE HealthCare’s radiopharmaceutical footprint.
  • Transaction includes U.S. rights to Phase III PET radiotracer FAPI-74, which GE HealthCare already holds outside the U.S.
  • SOFIE is expected to keep supplying PET products to existing customers, including products from other radiopharmaceutical providers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610050800BIZWIRE_USPR_____20261005_BW273717) on October 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.